# Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer

> **NCT06088030** · PHASE2 · RECRUITING · sponsor: **Yang Li** · enrollment: 50 (estimated)

## Conditions studied

- Pediatric Cancer
- Li-Fraumeni Syndrome
- p53 Mutations

## Interventions

- **DRUG:** Arsenic trioxide

## Key facts

- **NCT ID:** NCT06088030
- **Lead sponsor:** Yang Li
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-13
- **Primary completion:** 2031-12-14
- **Final completion:** 2031-12-14
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2024-01-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06088030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06088030, "Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06088030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*